What BCN PEPTIDES does

BCN Peptides is a privately held Spanish contract development and manufacturing organization (CDMO) headquartered in Sant Quintí de Mediona near Barcelona, specializing in the GMP-compliant manufacture of bioactive peptide Active Pharmaceutical Ingredients (APIs). Founded in 1989 and operating as a subsidiary of the Volsunga Group, the company has built 35+ years of specialized expertise in Solid Phase Peptide Synthesis (SPPS), with capabilities spanning milligrams to multi-kilogram batches, including complex long sequences and cyclic peptides for both sterile and non-sterile applications. The company holds multi-jurisdictional GMP certifications from the US FDA, EDQM, PMDA Japan, and other national authorities, and operates a vertically integrated service stack covering custom synthesis, analytical method development, ICH stability studies, regulatory dossier preparation (DMF, IMPD/IND, CEP), and project management from preclinical through commercial phases.

The company's revenue model combines enterprise CDMO contracts (quote-based, project-managed manufacturing for pharmaceutical and biotech clients) with a self-serve e-commerce channel for research-grade peptides through shop.bcnpeptides.com, which lists more than 1,000 catalog references. BCN Peptides serves four primary customer segments — pharmaceutical companies (GMP API supply), biotechnology firms (custom synthesis and personalized neoantigen therapies via its dedicated PPM Laboratory operational since 2020), the cosmetic industry (e.g., Acetyl Hexapeptide-8), and academic/research institutions. Distribution is centered on direct enterprise field sales at global industry conferences (CPHI, TIDES, BIO, European/American Peptide Symposiums) plus online self-service for research-grade products. Beyond contract manufacturing, the company maintains a proprietary R&D pipeline including the RA08 anti-metastasis peptide (PCT/EP2020/083987) and collaborates with leading European research institutes including Vall d'Hebron, IRB Barcelona, and IBiS Seville on oncology and inflammatory disease programs.

Name

BCN PEPTIDES

Legal name

BCN PEPTIDES, S.A.U.

Website

https://bcnpeptides.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Short description

BCN Peptides is a privately held Spanish GMP peptide CDMO founded in 1989, specializing in Solid Phase Synthesis of peptide APIs (generic, custom, neoantigen, and cosmetic) from milligrams to multi-kg batches, serving pharmaceutical, biotech, cosmetic, and research customers globally with FDA/EDQM/PMDA certifications.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO / Peptide Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• GMP peptide manufacturing
• Contract development manufacturing
• Custom peptide synthesis
• Peptide API production
• Research-grade peptides

Headquarters

HQ city

Mediona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. GMP Peptide Manufacturing: Commercial supply of fully GMP API for global markets, including generic peptides and custom synthesis for preclinical, clinical and commercial phases.
2. Research-Grade Peptides: Online shop offering extensive catalog of research grade peptides with e-commerce purchasing capability for research institutions and companies.
3. Custom Synthesis Services: Custom synthesis of New Chemical Entities (NCEs) for preclinical, clinical and commercial stages, including project management and regulatory support.
4. Cosmetic Peptides: Peptides for cosmetic formulations including Acetyl Hexapeptide-8 and other anti-aging skin care active ingredients.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

BCN Peptides is a CDMO specializing in the cGMP industrial manufacture of bioactive peptides using Solid Phase Peptide Synthesis technology. The company produces GMP Active Pharmaceutical Ingredients (APIs) from milligrams to multi-kilogram batches for pharmaceutical, biotech, and cosmetic clients. Core offerings include commercial supply of generic peptide APIs, custom synthesis of New Chemical Entities for preclinical through commercial phases, GMP neoantigen peptides for personalized medicine, cosmetic peptides for skincare applications, and an online catalog of over 1,000 research-grade peptide references.

Product overview

BCN Peptides is a European GMP API manufacturing company and CDMO based in Barcelona with over 35 years of experience in peptide synthesis. The company operates as a single integrated platform offering four core product lines: Generic Peptides (commercial GMP API supply), Custom Synthesis/NCEs (custom manufacturing for clinical and commercial phases), NeoAntigen Peptides (personalized medicine production), and Cosmetic Peptides. Supporting these products are comprehensive services including GMP Manufacturing, Analytical Support, Regulatory Affairs, and Project Management. The company also operates an e-commerce platform (shop.bcnpeptides.com) offering over 1,000 research-grade peptide references across categories including bioactive peptides, cancer neoantigens, COVID-19 peptides, synthetic proteins, and miscellaneous peptides. BCN Peptides manufactures from milligrams to multi-kg batches using Solid Phase Synthesis technology and holds regulatory approvals from US FDA, EDQM, PMDA Japan, and other national authorities worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Peptides (GMP API) Commercial supply of fully GMP Active Pharmaceutical Ingredients (API) for global pharmaceutical markets. Targets pharmaceutical companies requiring peptide APIs for generic drug formulations and commercialization.
• Custom Synthesis / New Chemical Entities (NCEs) Custom synthesis of New Chemical Entities for preclinical, clinical, and commercial phases using Solid Phase Synthesis. Specialized in long sequences and cyclic peptides for pharmaceutical and biotech customers.
• NeoAntigen Peptides Production of GMP peptides for personalized medicine including the Peptide-based Personalized Medicine (PPM) laboratory for individual patient-specific neoantigen therapies, primarily for oncology applications.
• Cosmetic Peptides Peptides designed for cosmetic and personal care applications targeting collagen stimulation, wrinkle reduction, and skin elasticity improvement. Includes Acetyl Hexapeptide-8 and other anti-aging active ingredients for cosmetic companies.
• Research-Grade Peptides Online Shop Extensive e-commerce catalog of over 1,000 research-grade peptide references available for online purchase, serving research institutions and companies. Includes bioactive peptides, API impurities, SARS-CoV-2/COVID-19 peptides, cancer neoantigens, antigen peptides, and synthetic proteins.
• GMP Manufacturing Services Full-scale GMP manufacturing from milligrams to multi-kg batches covering route development, scaling up, process validation, and commercial manufacturing of both sterile and non-sterile peptide API.
• Analytical Support Services Comprehensive analytical services including characterization, working standard preparation, specification establishment, analytical method development and validation, ICH stability studies, and pharmaceutical final product analysis.
• Regulatory Affairs Services Regulatory and registration support including Drug Master Files, IMPD/IND submissions, EP-Certificates of Suitability (CEP), and NDA/MAA registration support for Europe, US, Japan, and worldwide markets.
• Synthetic Proteins (Native Chemical Ligation) Synthetic proteins produced via Native Chemical Ligation (NCL) for structural studies, functional assays, and diagnostic protein applications, addressing capabilities beyond what recombinant methods can produce.

Quantifiable outcome

• Successful GMP renewal following regulatory inspections by European Authorities (Part I: sterile peptides and contract laboratory; Part II: entire peptide portfolio)
• +3 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• GAPVAC European ConsortiumcoreStrategic or Co-development Partner · 20 December 2018BCN Peptides was a key GAPVAC European Consortium member that performed the first-in-human Clinical trial of a Personalized Therapeutic Vaccine to treat Glioblastoma. BCN Peptides manufactured the GMP Peptide Library used for Vaccine production. The proof-of-concept for the personalized approach was published by Nature on December 19, 2018.
• Vall d'Hebron Research Institute (VHIR)coreStrategic or Co-development PartnerStudy led by BCN Peptides and the Childhood Cancer and Blood Disorders group at VHIR demonstrating efficacy of new drug RA08 to reduce metastasis formation in childhood and breast cancer. Work published in Cellular and Molecular Life Sciences. Collaboration included Pediatric Oncology, Hematology, Pediatric Surgery, and Pathological Anatomy Services of Vall d'Hebron University Hospital.
• Institut de Recerca Biomèdica (IRB Barcelona)coreStrategic or Co-development PartnerMultidisciplinary collaboration with IRB Barcelona researchers for development of peptide analog therapy for inflammatory bowel disease (Crohn disease and ulcerative colitis). Results published in Nature Communications demonstrating greater efficacy than current treatments (infliximab and mesalazine) in preclinical models.
• Instituto de Parasitología y Biomedicina López Neyra – CSIC Granada (IPBLN-CSIC)coreStrategic or Co-development PartnerCollaboration on inflammatory bowel disease research with researchers from IPBLN-CSIC Granada. The peptide analog of Cortistatin showed anti-inflammatory and immune modulatory effects with improved systemic half-life.
• Institute of Biomedicine of Seville (IBiS)coreStrategic or Co-development PartnerCollaboration on research demonstrating efficacy of RA08 peptide for metastasis prevention. IBiS researchers contributed to the study on role of integrin alpha9 (ITGA9) in tumor invasion in neuroblastoma and rhabdomyosarcoma models.
• IDP-PharmaminorStrategic or Co-development PartnerBCN Peptides supports IDP-Pharma in development of a new chemical entity aimed to treat Multiple Myeloma. Collaborative project granted funds from European Union FEDER via ACCIO and its 'Nuclis d'Innovació Tecnològica' program.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bachem: Bachem is the world's largest independent peptide CDMO, offering GMP peptide API manufacturing from preclinical to commercial scale across multiple global sites. It is the category leader BCN Peptides is most directly benchmarked against in customer evaluations.
• PolyPeptide Group: PolyPeptide is a publicly listed, Switzerland-based specialist peptide CDMO with global manufacturing and a broad generic and custom peptide API portfolio. Like BCN Peptides, it serves pharma and biotech customers from clinical to commercial supply.
• CordenPharma: CordenPharma is a global CDMO with a dedicated peptide manufacturing platform spanning from custom synthesis to commercial GMP API. It is one of the few full-service peptide CDMOs that BCN Peptides' sales team regularly competes against.
• AmbioPharm: AmbioPharm is a US-headquartered peptide CDMO operating large-scale GMP manufacturing facilities for both generic and custom peptide APIs. Its production scale and FDA-approved footprint make it a directly comparable rival for BCN Peptides' commercial peptide contracts.
• CSBio: CSBio is a US-based peptide contract manufacturing organization offering peptide synthesis, cGMP manufacturing, and custom peptide services. It competes in the same mid-sized peptide CDMO segment targeted by BCN Peptides' enterprise sales motion.
• Piramal Pharma Solutions: Piramal is a large global CDMO with established peptide API manufacturing capabilities alongside broader injectable and small-molecule services. Its peptide offering directly competes for the same pharmaceutical customer programs BCN Peptides targets.
• Vivitide: Vivitide (formerly Bachem Americas, acquired by Genesis Healthcare) provides custom peptide synthesis and cGMP peptide API manufacturing for pharma and biotech. It overlaps with BCN Peptides' custom NCE and neoantigen peptide business.
• CPC Scientific: CPC Scientific is an Asia-based peptide CDMO offering custom synthesis, GMP manufacturing, and peptide analytical services to global pharmaceutical clients. It is a comparable competitor in cross-border peptide API outsourcing that BCN Peptides encounters.

Regional players

• Peptide Institute: Peptide Institute is a Japan-headquartered specialist peptide manufacturer with deep technical expertise and Asian regulatory standing (PMDA). It is a regional peer addressing Japanese pharma customers that BCN Peptides targets via its CPHI Japan presence.

Emerging players

• Novaptech: Novaptech is a smaller European peptide services company offering custom peptide synthesis and bioconjugation. It is a niche, geographically proximate peer focused on research-grade and specialty peptides rather than large-scale GMP API.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bcn-peptides

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BCN PEPTIDES